P
9.99
-0.70 (-6.55%)
| Previous Close | 10.69 |
| Volume | 188,264 |
| Price / Sales | 2.40 |
| Price / Book | 3.95 |
| 52 Weeks Range |
| Profit Margin | 16.36% |
| Operating Margin (TTM) | 8.66% |
| Diluted EPS (TTM) | 0.780 |
| Quarterly Revenue Growth (YOY) | 5.10% |
| Quarterly Earnings Growth (YOY) | 57.40% |
| Total Debt/Equity (MRQ) | 63.55% |
| Current Ratio (MRQ) | 1.53 |
| Operating Cash Flow (TTM) | 31.28 M |
| Levered Free Cash Flow (TTM) | 19.67 M |
| Return on Assets (TTM) | 11.35% |
| Return on Equity (TTM) | 51.41% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Puma Biotechnology Inc | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.5 |
| Relative Valuation | 5.0 |
| Financial Health | 2.6 |
| Macro Environment | -1.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | 0.17 |
Select this tab to load the latest available analysis.
|
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 15.87% |
| % Held by Institutions | 65.68% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Acorn Capital Advisors, Llc | 30 Jun 2026 | 4,131,299 |
| American Century Companies Inc | 30 Jun 2026 | 2,319,996 |
| Acadian Asset Management Llc | 30 Jun 2026 | 2,053,523 |
| Renaissance Technologies Llc | 30 Jun 2026 | 1,836,213 |
| Lsv Asset Management | 30 Jun 2026 | 1,617,981 |
| O'shaughnessy Asset Management, Llc | 30 Jun 2026 | 1,123,783 |
| Kennedy Capital Management Llc | 30 Jun 2026 | 873,253 |
| Bridgeway Capital Management, Llc | 30 Jun 2026 | 791,616 |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |